Homozygous HSD3B1 (1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean …
N Sharifi - Annals of Oncology, 2020 - annalsofoncology.org
A major challenge in prostate cancer is identifying genetic biomarkers that serve as
indicators of clinical behavior and are useful for clinical management. 1 Clinical states of
metastatic prostate cancer are defined by dependence on androgens and resistance to
hormonal therapies [eg castration-sensitive prostate cancer (CSPC) and castrationresistant
prostate cancer (CRPC)]. Multiple metabolic and molecular pathways allow for development
of CRPC, as evidenced by the widely variable clinical responses to nextgeneration …
indicators of clinical behavior and are useful for clinical management. 1 Clinical states of
metastatic prostate cancer are defined by dependence on androgens and resistance to
hormonal therapies [eg castration-sensitive prostate cancer (CSPC) and castrationresistant
prostate cancer (CRPC)]. Multiple metabolic and molecular pathways allow for development
of CRPC, as evidenced by the widely variable clinical responses to nextgeneration …